MedTrace Logo

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2023-07-24

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

Conditions

  • Resistant Hypertension

Interventions

DRUG

CIN-107

CIN-107 tablets by mouth once daily

DRUG

Placebo

placebo tablets by mouth once daily

Sponsors & Collaborators

  • CinCor Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-12
Primary Completion
2022-06-14
Completion
2022-06-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519658 on ClinicalTrials.gov